



FOR IMMEDIATE RELEASE

Contact:  
Lynda Sutton  
President  
Cancer Advances, Inc.  
Phone: 919-361-2162  
email: [info@canceradvancesinc.com](mailto:info@canceradvancesinc.com)  
[www.canceradvancesinc.com](http://www.canceradvancesinc.com)

## **Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products**

**Durham, NC, March 22, 2013** — Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the issuance of three new patents. Two of the newly released patents cover monoclonal antibodies to progastrin and have been issued in the United States and Australia. The third patent is for a companion diagnostic immunoassay issued in Canada which was previously issued earlier in the year for the United States. Collectively, these patents are additive parts to Cancer Advances' suite of products that work to inhibit the cancer causing hormone, gastrin 17.

Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.

The two progastrin patents cover a pharmaceutical composition, comprised of a progastrin-binding molecule that selectively binds to progastrin, a monoclonal antibody to progastrin, and an immunoassay to determine the amount of progastrin in a sample. These patents also cover a method of monitoring treatment of a gastrin-promoted disease or by determining the level of progastrin in a patient.

The third patent, which covers a companion diagnostic immunoassay, is used for the detection and quantitation of gastrin hormones found in a biological fluid

Cancer  
Advances is  
DEDICATED  
to enhancing  
the immune system  
and augmenting  
human quality of life by  
targeting the progression  
of gastrointestinal cancers.

**Cancer Advances**  
P | 919-361-2162  
E | [info@canceradvancesinc.com](mailto:info@canceradvancesinc.com)  
[www.canceradvancesinc.com](http://www.canceradvancesinc.com)



sample such as blood. It allows oncologists to identify and target patients who will receive the greatest benefit from treatment with PAS. Slowing tumor growth, improving quality of life, and extending survival for patients suffering from a gastrin hormone-mediated disease are all accomplishments that Cancer Advances has continually strived toward in its research.

“Cancer Advances continues to produce products that progress our efforts in the fight against gastrin-related diseases,” says Lynda Sutton, president of Cancer Advances.

For more information, please contact:

Lynda Sutton

President, Cancer Advances

[lsutton@cato.com](mailto:lsutton@cato.com)

919-361-2162

[www.canceradvancesinc.com](http://www.canceradvancesinc.com)

### **About Cancer Advances**

Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

Please visit our product page for more information on what is in development:

<http://www.canceradvancesinc.com/product.html>

###

Cancer  
Advances is  
DEDICATED  
to enhancing  
the immune system  
and augmenting  
human quality of life by  
targeting the progression  
of gastrointestinal cancers.

**Cancer Advances**

P | 919-361-2162

E | [info@canceradvancesinc.com](mailto:info@canceradvancesinc.com)

[www.canceradvancesinc.com](http://www.canceradvancesinc.com)